JSN_TPLFW_TOGGLE_MENU

 

Until now, experts in the USA had expressly spoken out against a widespread use of the PSA test for the early detection of prostate cancer. Since then the US Preventive Services Task Force (USPSTF) has revised their negative judgment about its benefits. The 180-degree turnaround is due to new study results showing a clear decrease in mortality and metastasis in PSA-tested men, as well as a reassessment of the American PSA screening study (PLCO).

Experts in the USA criticized the PSA test mainly as a result of an American study in-volving more than 75,000 patients published in the New England Journal of Medicine in 2012. There was no difference between men who had testing for the prostate spe-cific antigen (PSA) in the blood and those who did not. However, a recent analysis of the study1 revealed major methodological shortcomings. In retrospect, for example, it was found that 90 percent of the allegedly untest-ed men had secretly tested themselves and, if necessary, even had treatment.

Survival benefit and lower risk of metastasis

In addition, an updated evaluation of the European study (ERSPC study) published for the first time in 2009 motivated the US expert panel to reassess the significance of PSA testing in the early detection of prostate cancer. Thereafter, regular screening of the PSA level leads to fewer metastases and reduces mortality by prostate cancer. The study shows that prostate cancer mortality can be reduced by around 20 percent in 13 years through PSA screening.


“This is clear evidence of the benefits of PSA testing in prostate cancer screening," says Dr. Stephan Neubauer from the West German Prostate Center in Cologne. However, according to the urologist, the correct handling of the test results is essential for the further procedure. It often happens that PSA values are misinterpreted and action is taken prematurely. For example, benign prostate enlargement or inflammation can lead to increased but harmless PSA levels. “It is always essential to have a professional-founded evaluation of a man's overall findings and not an isolat-ed evaluation of the PSA”, summarizes Dr. Neubauer.


1 Shoag JE1, Mittal S1, Hu JC2.: Reevaluating PSA Testing Rates in the PLCO Trial. N Engl J Med. 2016 May 5;374(18):1795-6. doi: 10.1056/NEJMc1515131.

2Schröder FH et al.: Screening and prostate-cancer mortality in a randomized Euro-pean study. N Engl J Med. 2009 Mar 26;360(13):1320-8. Epub 2009 Mar 18.

mdc plakette 9001 d1focus2017

Berichte über das Westdeutsche Prostatazentrum

                 qrcodeWPZ
           QR-Code der Kontaktdaten

Westgerman Prostate Center

Klinik am Ring
Hohenstaufenring 28
50674 Köln, Germany
Tel.: +49-221-92424-470
Fax: +49-221-92424-460
This email address is being protected from spambots. You need JavaScript enabled to view it.

 

News

Radiation or Surgery for Prostate Cancer?

Radiation or surgery for prostate cancer? No other cancer disease causes opinions to differ as widely as does prostate cancer.

Ten misconceptions about the treatment of prostate cancer

Surgery, radiotherapy or just wait and see? Prostate cancer like no other type of cancer, creates so many misinformation

US panel of experts again recommends PSA test for early detection
Decrease in mortality and metastasis in PSA-tested men
FOCUS doctor's advice for Dr. Stephan Neubauer

Dr. Stephan Neubauer is recommended by FOCUS HEALTH twice as a TOP physician.

No Disadvantage due to delayed Therapy

Men diagnosed with a localized prostate carcinoma should not be placed under pressure in their choice of treatment

PSMA-PET / CT: Local recurrence or metastatic tumor?

CHAPPP:Study: Higher hit rate of metastasis due to PSMA-PET / CT

Extensive Database secures Treatment Quality

Prostate Cancer Patients benefit from the close Follow-up in the Westgerman Prostate Center

Go to top